Notably, the product previously received fast track designation from the FDA for relapsed/refractory class III or class IV lupus nephritis.
Abigail Brooks, MA
Advertisement
Abigail Brooks is an assistant editor for HCPLive. She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at [email protected].
Articles by Abigail Brooks, MA
Advertisement
